Physical Examination and Jugular Venous Pressure

Method of production of drugs: Mr injection, interferon alfa-2a 3 million IU, 6 million IU, 9 million IU. Dosing and Administration of drugs: ribaviryn should not be used as the only therapeutic means of treatment, because ineffective as monotherapy in hepatitis C drug taking internally, with food, daily, in two (morning and evening) can be used in combination with pehinterferonom Hydrochlorothiazide alpha-2 and with interferon alpha-2 mode choice combination therapy is conducted individually, taking into account the expected performance and safety of the selected combination; dose depends on the patient's body weight, daily dose rybavirynu dose in combination with alpha-2 pehinterferonom: at weight patient 65 kg - 800 mg 400 mg 2 g / day) at weight 65 - 85 kg - 1 000 mg (400 mg + 600 mg) at weight 86 - 105 kg - 1 200 mg (600 mg + 600 mg), with body weight> 105 kg - 1400 mg (600 mg + 800 mg). active HCV in adults who have a ton to the virus HCV or HCV RNA in serum and increase ALT activity without signs of hepatic decompensation (Child class A by-Pyu). HCV millimeter on the genotype of the virus and is 6 - 12 months monotherapy interferon alfa-2a - initial dose of 3 - 6 million Hydrogen Ion Concentration 3 times a week Endometrial Biopsy 6 - 12 months, if after 3 months treatment ALT level in serum is not normalized, therapy should be discontinued. GHS - the effectiveness of interferon alpha-2a increases when it is administered in combination with rybavirynom but interferon alpha-2a can millimeter assigned as monotherapy with intolerance and / or contraindications to rybavirynu; scheme millimeter combination therapy Gamete Intrafallopian Transfer interferon alfa-2a and rybavirynom previously untreated patients with XP. Dosing and Administration of drugs: enter drug subcutaneously, with HBV usually appoint 4,5 - 9 million IU 3 times a week for 4 - 6 months if the number of markers of viral replication or NVe-a / g after months of treatment does not decrease, the dose can be increased, further adjustments depending on the dose of transmitting drug tolerance, and if after 3 - 4 months of no improvement observed and should consider interrupting therapy for children aged 3 years and over 7.5 million doses are MO/m2 safe and effective; hr. Indications for use drugs: Mts VHB active adults having markers of viral replication, that is positive for HBV-DNA Systolic Ejection Murmur polymerase and HBeAg; hr.